MOTS-c for Post-COVID and Long-COVID Recovery: A Structured Clinical Protocol

The direct answer

MOTS-c is a mitochondrially encoded peptide whose laboratory-studied actions on AMPK, mitochondrial biogenesis, and inflammatory signaling overlap mechanistically with abnormalities that have been reported in long-COVID, including mitochondrial dysfunction and persistent inflammation. That overlap is a reason for research interest, not evidence of clinical benefit: no completed randomized controlled trial has tested MOTS-c in people with long-COVID, and the only registered human trial identified for this peptide (ClinicalTrials.gov NCT05683366) is a phase I safety and pharmacokinetics study in older adults that is not restricted to long-COVID and has not published results. Anyone considering MOTS-c for post-COVID symptoms is using a compounded, non-FDA-approved peptide off-label, ahead of the trial evidence that would normally establish a dose, a monitoring standard, or an expected benefit.

The realistic clinical question for a patient and physician is not "does MOTS-c's mechanism make biological sense for long-COVID", it plausibly does, but whether that plausibility is strong enough to justify off-label use in an individual patient before safety and efficacy data exist, and what specific stopping rules will protect that patient if it does not help or causes harm.

What long-COVID is, and where the uncertainty begins

Long-COVID, also described as post-COVID conditions or Post-Acute Sequelae of SARS-CoV-2 infection (PASC), refers to a range of symptoms that persist or develop after acute SARS-CoV-2 infection, commonly including fatigue, post-exertional malaise, cognitive difficulties ("brain fog"), and autonomic symptoms. The CDC maintains an overview of the condition, its definition, and its recognized long-term effects, and that page should be treated as the primary reference for definitions and general epidemiology rather than any peptide-focused source (verify current figures at the CDC long-term effects page, checked January 2025).

Research groups have proposed several contributing mechanisms for long-COVID symptoms, including mitochondrial dysfunction in immune and muscle cells, persistent low-grade inflammation, and dysregulated T-cell responses. These mechanisms are described across a body of observational and small mechanistic studies. This article does not carry forward the specific numeric findings, journal names, or PMIDs from those studies because they could not be independently verified against the primary literature for this draft. Readers and reviewing clinicians should treat any precise percentage, sample size, or statistical claim about long-COVID mitochondrial or immune findings as requiring direct verification in PubMed or the cited journal before it is used in patient materials or clinical documentation.

What is established: long-COVID is a real, CDC-recognized cluster of persistent post-infection symptoms; fatigue, post-exertional malaise, and cognitive complaints are core features; and mitochondrial and inflammatory abnormalities have been reported in multiple independent research groups studying long-COVID, in general terms.

What is plausible but unproven: that correcting mitochondrial signaling pharmacologically (with MOTS-c or any other agent) improves long-COVID symptoms in a clinically meaningful, durable way.

What is not established: any specific dose, treatment duration, biomarker response magnitude, or symptom-resolution timeline for MOTS-c in long-COVID, because no completed trial in this population exists.

What MOTS-c is and how it is thought to work

MOTS-c belongs to a small family of mitochondrial-derived peptides encoded within mitochondrial DNA rather than the nuclear genome. Preclinical work in animal models has associated MOTS-c administration with activation of AMP-activated protein kinase (AMPK), a central regulator of cellular energy balance, with downstream effects on inflammatory signaling pathways such as mTORC1 and on transcription factors in the FOXO family that influence mitochondrial gene expression and immune cell regulation. Exercise has been reported to raise circulating MOTS-c levels in some human studies, which has led some researchers to describe it as an exercise-responsive mitochondrial signal.

This mechanistic profile is why MOTS-c has drawn interest for conditions marked by exercise intolerance, fatigue, and low-grade inflammation, including chronic fatigue syndromes and, more recently, long-COVID. It is mechanistic plausibility, built from animal pharmacology and small human observational studies conducted largely outside the long-COVID population. It has not been confirmed as a clinical mechanism of benefit in PASC specifically, and the foundational animal studies used doses and routes of administration that do not translate directly to a validated human dose.

Evidence hierarchy: what actually supports use in long-COVID

Ranked from strongest to weakest form of evidence currently available:

1. FDA status. MOTS-c has no FDA-approved indication. It is not a recognized prescription drug; it is obtained only as a compounded preparation. This is the most load-bearing fact for any prescribing decision.
2. Guideline recommendations. No major guideline body (CDC, NICE, or comparable) recommends MOTS-c for long-COVID. The UK's NICE long-COVID guidance (NG188) has previously cautioned against graded exercise therapy and favored energy management (pacing) as a behavioral cornerstone; this is a guideline-level recommendation about activity management, not about MOTS-c, and should not be conflated with peptide-specific advice.
3. Trial evidence. One registered trial, NCT05683366, is evaluating MOTS-c safety and pharmacokinetics in adults aged 40 to 70. It is not restricted to a long-COVID population, is listed as a phase I study, and had not published results as of this review. No completed randomized trial of MOTS-c in long-COVID exists.
4. Mechanistic and animal data. Multiple animal studies and small human mechanistic studies, conducted mostly outside the long-COVID population, have examined MOTS-c effects on metabolism, inflammation, and mitochondrial function. These support a biological rationale, not a clinical claim, and the specific figures reported in secondary summaries require verification against the original papers before being used in clinical materials.
5. Practitioner-reported experience. Off-label clinical use is documented anecdotally by practitioners administering MOTS-c for fatigue-related and post-viral conditions. This is the weakest form of evidence in the hierarchy and should not be presented to patients as equivalent to trial data.

Structured off-label protocol as reported in practice

The following reflects patterns described in off-label clinical use and is not a validated, guideline-endorsed protocol. It is included to make the current state of practice transparent, not to recommend a specific dose. Any decision about starting, adjusting, or stopping MOTS-c belongs to the treating physician working with an individual patient's history, labs, and risk factors, this article cannot and does not provide individualized dosing instructions.

Clinician-patient discussion and monitoring framework

The boundary this framework is meant to enforce: everything above the table (FDA status, absence of RCTs, guideline silence) is label-level and evidence-level fact that applies to every patient. Everything in the table is a structure for an individualized conversation, not a protocol to be applied uniformly. A physician may reasonably deviate from every checkpoint above based on an individual patient's full picture; this framework is a discussion aid, not a substitute for that judgment.

Reported dosing patterns (descriptive, not prescriptive)

Practitioner-reported off-label use has described subcutaneous injections in the range of roughly 5 to 10 mg, several times per week, in cycles of around 8 weeks followed by a rest period, with adjustments made based on tolerability and lab trends. These figures come from practitioner experience rather than a dose-finding trial, so they should be understood as a description of current practice patterns, not a validated or recommended dose. The ongoing NCT05683366 phase I trial may eventually establish safety and pharmacokinetic data that supersedes this practitioner-reported range.

Expected timeline, and its limits

Practitioner reports and analogy to animal-study timeframes suggest that if a physiological response occurs, inflammatory markers might shift within the first several weeks, subjective cognitive or sleep changes might precede fatigue improvement, and any change in exercise tolerance would likely take longer to become measurable. No study has established this timeline in a long-COVID population, and clinicians should avoid presenting it to patients as an expected or guaranteed course.

Combination approaches sometimes used alongside MOTS-c

Off-label practitioners often pair MOTS-c with other supportive measures. Each has its own separate evidence base, and none has been tested in combination with MOTS-c in a controlled study:

• NAD+ precursors (nicotinamide riboside or nicotinamide mononucleotide) are studied for supporting the NAD+ pool involved in mitochondrial energy metabolism. Evidence for these compounds in long-COVID specifically requires separate verification and is outside the scope of this article.
• Low-dose naltrexone has been studied observationally in post-COVID fatigue and related conditions. It is a distinct intervention with its own risk profile and prescribing considerations and should be evaluated on its own evidence, not assumed to add to MOTS-c's effect.
• Pacing and energy management, rather than graded exercise, is the behavioral approach favored in NICE's long-COVID guidance. Any peptide protocol that ignores pacing and pushes exertion beyond a patient's tolerance risks worsening post-exertional malaise regardless of what is injected.

Safety profile and who should not use MOTS-c off-label

No completed human safety trial of MOTS-c in a long-COVID population exists. The available safety signal comes only from the ongoing phase I trial (not yet reporting results), animal pharmacology, and off-label practitioner reports, which are the least reliable source of safety data in this hierarchy.

Reported off-label adverse effects include transient injection site redness or warmth, occasional early fatigue increase, and headache at higher doses. No serious adverse events specific to MOTS-c have been established in peer-reviewed literature verified for this draft. Because long-term human data do not exist, theoretical risks include effects on FOXO-family tumor-suppressor pathways, immune activation in patients with underlying autoimmune disease, and unknown interactions with immunosuppressive or anticoagulant medications.

Patients on anticoagulants, biologics, or mTOR inhibitors, and patients with active malignancy, pregnancy, or an active autoimmune flare, should not use MOTS-c without explicit clearance from the relevant specialist. Anyone experiencing chest pain, severe shortness of breath, neurological symptoms, or signs of a serious allergic reaction after any injection should seek urgent medical care rather than waiting for a scheduled follow-up.

Regulatory and sourcing status (verify before use)

As of January 2025, MOTS-c has no FDA-approved indication and is available only through compounding pharmacies operating under a physician's prescription. The FDA has been actively reviewing bulk drug substances used in compounding, and the regulatory environment for research peptides, including MOTS-c, can change. Anyone considering this peptide should verify its current compounding status directly with a prescribing physician and an accredited pharmacy rather than relying on this article's regulatory description, which may be out of date by the time it is read.

MOTS-c should be obtained only through a licensed physician working with an accredited compounding pharmacy. Purchasing it from unregulated online suppliers removes quality and safety controls entirely and is not advisable.

Where this leaves a patient and physician

MOTS-c's biological rationale for long-COVID is coherent: mitochondrial dysfunction and inflammatory signaling are documented features of the syndrome, and MOTS-c's studied mechanisms touch both. Coherence is not confirmation. Until a controlled trial in a long-COVID population exists, any use is an off-label trial of one, and it should be treated that way in documentation, consent, and follow-up: a defined trial period, defined stopping rules, and an honest baseline expectation that benefit is unproven rather than likely.